<style type="text/css"> .wpb_animate_when_almost_visible { opacity: 1; }</style>

  • Using technology in tumor genomics to develop precision cancer therapeutics

    Investor Relations

Press Releases

Archives: Search / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012

2012 Archives

Dec 26, 2012
Trovagene, Inc., Grants License for NPM1 Marker for Acute Myelogenous Leukemia to Leading Academic Medical Center
Dec 19, 2012
Trovagene, Inc., Continues to Expand NPM1 Licensing Program for Acute Myelogenous Leukemia
Nov 27, 2012
Trovagene to Introduce First Urine-Based Molecular Diagnostic Test for Transrenal Cancer Mutation Monitoring
Nov 26, 2012
Trovagene and Barretos Cancer Hospital, Brazil, to Evaluate Urine-Based HPV Assay as Potential Pap Smear Replacement
Nov 21, 2012
Trovagene Announces Closing of Private Placement of $3.76 Million from the Sale of Restricted Common Stock and Warrants
Nov 18, 2012
Dr. Paul Billings joins Trovagene's Scientific Advisory Board
Renowned molecular geneticist strengthens Trovagene's scientific expertise
Nov 14, 2012
Trovagene, Inc., Announces Third Quarter and Year to Date Earnings, Provides Milestone Update
COMPANY CONTINUES TO DEVELOP PROGRAMS IN CANCER AND INFECTIOUS DISEASE DETECTION IN URINE
Sep 19, 2012
Trovagene and Strand Life Sciences Agree to Validate and Commercialize Urine-Based HPV Test in India and South Asia
Sep 12, 2012
Trovagene, Inc., Grants License for NPM1 Marker to Quest Diagnostics for Acute Myelogenous Leukemia
Sep 4, 2012
Trovagene, Inc. to Present at the Rodman & Renshaw Annual Global Investment Conference
Aug 28, 2012
Trovagene, Inc., Achieves Intellectual Property Milestone under License Agreement with Ipsogen
Issuance of First US NPM1 Patent Triggers Milestone Payment
Aug 14, 2012
Trovagene, Inc. Announces Second Quarter and Year to Date Earnings, Provides Milestone Update
COMPANY CONTINUES TO EXPAND PROGRAMS IN CANCER AND INFECTIOUS DISEASE DETECTION IN URINE
Jul 17, 2012
Trovagene, Inc., Announces Issuance of U.S. Patent for NPM Mutants to Diagnose and Monitor Acute Myeloid Leukemia
Jul 2, 2012
Trovagene to Study Trans-Renal KRAS Mutation Detection in Pancreatic Cancer
Study will compare detection of KRAS mutations in urine to their detection in biopsy samples
Jun 24, 2012
Trovagene to be Added to Russell Microcap Index
Jun 13, 2012
Trovagene, Inc. Announces Full Exercise of Over-Allotment Option by Aegis Capital Corp.
Jun 6, 2012
Trovagene and Strand Life Sciences Plan Collaboration to Validate and Offer Urine-Based HPV Screening Test in India and South Asia
May 30, 2012
Trovagene, Inc. Announces Pricing of Public Offering of 1,150,000 Units, Listing on NASDAQ and Effectiveness of Reverse Stock Split
May 29, 2012
Trovagene, Inc. Announces Pricing of Public Offering of 1,150,000 Units, Listing on NASDAQ and Effectiveness of Reverse Stock Split
May 9, 2012
Trovagene, Inc., Announces Issuance of European Patent for Detection of Pathogenic Infections
May 1, 2012
Trovagene Announces Plans to Develop Proprietary Test for High Risk HPV Carrier Screening from Urine
Apr 30, 2012
Dr. Carlo Croce joins Trovagene as Scientific Consultant and Member of the Company's Scientific Advisory Board
Internationally recognized cancer researcher and physician strengthens Trovagene's scientific expertise in cancer genetics
Apr 30, 2012
Trovagene Announces Validation Program for Trans-Renal K-RAS Mutation Detection in Pancreatic Cancer
Company plans to establish comprehensive panel of assays to detect oncogene mutations in the urine of cancer patients
Apr 22, 2012
Keith McCormick Joins Trovagene, Inc. as Head of Commercial Operations
- Pharmaceutical and diagnostic sales and marketing executive will provide leadership to accelerate commercial programs -
Feb 26, 2012
Trovagene Expands Business Development Efforts Through a Partnership with Leomics Associates, Inc.
1-25      26-30
 

email print rss
3:34
3:34
Wistia video thumbnail - Susann-Berz Patient Video- Home Page
About WistiaReport a problemCopy link and thumbnail

Thanks for reporting a problem. We'll attach technical data about this session to help us figure out the issue. Which of these best describes the problem?

Any other details or context?

Cancel
message